Clinical characteristics, management, and outcomes of patients with primary cardiac angiosarcoma: A systematic review
- ,
- ,
- Rosalie M. Sterner,
- Ana Brañez-Condorena,
- Pedro Guerra-Canchari,
- John Stulak
- ,
- Torres de Salud National Research Center,
- Mayo Clinic,
- University of Massachusetts Chan Medical School,
- Facultad de Ciencias de la Salud,
- Universidad Nacional Mayor de San Marcos
Open access
Publication Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages 1-8 (8 pages)Journal (Volume, Issue Number)
Journal of Cardiovascular and Thoracic Research (Volume 15, Issue 1)Publication milestones
- Published - 03/2023
Publication status
ISSN
2008-5117Publication IDs
- Scopus: 85159639740
Abstract
Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors. Previous reports have shown a poor prognosis regardless of management, and no consensus or guidelines exist. It is necessary to clarify this information since patients with PCA have a short survival. Therefore, we aimed to systematically review clinical manifestations, management, and outcomes. We systematically searched in PubMed, Scopus, Web of Science, and EMBASE. We intended to include cross-sectional studies, case-control studies, cohort studies, and case series that reported clinical characteristics, management, and outcomes of patients with PCA. As a methodological approach, we used the Joanna Briggs Institute Critical Appraisal Checklist for Case Series and the Newcastle-Ottawa Scale for cohorts. We included six studies (five case series, one cohort). The mean/median age ranged from 39 to 48.9 years. Male sex was predominant. The most frequent manifestations were dyspnea (range: 50%-80%), pericardial effusion (29% & 56%), and chest pain (10%-39%). The mean tumor size ranged from 5.8 to 7.2 cm, with the majority of these localized in the right atrium (70-100%). The most common locations of metastasis were the lung (20%-55.6%), liver (10%-22.2%), and bone (10%-20%). Resection (22.9%-94%), and chemotherapy as neoadjuvant or adjuvant (30%-100%) were the most commonly used methods of treatment. Mortality ranged from 64.7% to 100%. PCA often presents late in its course and usually results in poor prognosis. We strongly recommend performing multi-institutional prospective cohorts to better study disease course and treatments to develop consensus, algorithms, and guidelines for this type of sarcoma.
